A consistent finding is that IL‐10 (the main Tregs effector cytokine) signaling transduction is accelerated in the brains of AD patients, and IL‐10‐deficient APP/PS1 mice show restricted cerebral amyloidosis and less cognitive decline than controls via a rebalancing of abnormal innate immunity (Guillot‐Sestier et al., 2015). The gene discussed is IL10; the disease is Alzheimer disease.